Medicus Pharma Regains Nasdaq Compliance After 10 Days Above $1 Bid-Price Threshold
Key Facts
Medicus Pharma said it received written notice on October 23, 2026, from Nasdaq’s Listing Qualifications Department that it had regained compliance with the minimum bid-price requirement and that the matter was closed. The notice followed the stock’s closing bid price remaining at $1 or more for 10 consecutive business days, from October 12 to October 23. This means the company resolved the minimum-price violation, according to a filing with the U.S. Securities and Exchange Commission. The development was directly relevant to the listing status of its common shares and warrants, after the company received a delisting determination letter days earlier. The company said the latest notice closed the price matter, while warning that continued compliance in the future is not assured.
Nasdaq sent the company a delisting determination letter on October 20, 2026, according to a Medicus filing; the compliance notice then nullified the effect of that earlier decision. The price violation was therefore closed three days after the delisting letter, while the bid-price measurement period had begun on October 12. The filing does not say Nasdaq issued a separate public announcement; the company said it received a notice from the Listing Qualifications Department. The action relates to the minimum bid-price requirement and does not confirm that all continued-listing requirements have been met. It also does not change the company’s warning about its ability to maintain compliance in future periods.
Before the measurement period, Medicus carried out a 1-for-50 reverse stock split, and its shares began trading on a post-split basis on October 12, 2026. The company said the goal of the action was to raise the bid price and help regain compliance with Nasdaq’s requirement. The start of post-split trading therefore coincided with the first day of the period Nasdaq used to count the required 10 business days. The compliance condition concerns the closing bid price, not the stock’s daily closing price; they are separate measures even when reported for the same date. Medicus shares, trading under the ticker MDCX, closed at $2.50 on October 23, compared with $2.62 on October 22 and $2.68 on October 21, according to EL7 data.
Medicus said in April that it had received a deficiency notice that had no immediate effect on the listing or trading of its shares on the Nasdaq Capital Market. The company said at the time it would monitor the closing bid price and could use available strategies to regain compliance. But the latest filing said the company was not eligible for a second 180-day compliance period because it did not meet the $5 million minimum stockholders’ equity requirement under the Nasdaq Capital Market’s initial listing standards. This background explains why meeting the price requirement within the measurement period mattered, since the additional compliance path cited in the filing was unavailable. The company lists its common shares on the Nasdaq Capital Market under the ticker MDCX and its warrants under MDCXW.
Medicus said in its filing that "there is no assurance that the Company will be able to maintain compliance" with the minimum bid-price requirement or other Nasdaq continued-listing requirements. That warning remains in place despite the closure of the current price violation, as it concerns the company’s ability to meet the requirements later. In April, the company said it would monitor the closing bid price and might, if it deemed appropriate, use available strategies to regain compliance; the reverse stock split later formed part of the actions it said were intended to raise the price. The current filing establishes that the price requirement was met for the specified period from October 12 to October 23 and says the delisting determination issued on October 20 was nullified. The filing did not set a date for any subsequent action, while retaining the warning that the company may fail to meet price or continued-listing requirements in the future.